Knight to Present at the 2023 RBC Capital Markets Global Healthcare Conference in New York City
May 09, 2023 13:00 ET
|
Knight Therapeutics
MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia,...
Notice of Knight Therapeutics' First Quarter 2023 Results Conference Call
May 04, 2023 07:30 ET
|
Knight Therapeutics
MONTREAL, May 04, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2023...
Knight to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 18, 2023 07:30 ET
|
Knight Therapeutics
MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia,...
Knight Therapeutics Inc. ranks on The Globe and Mail’s fourth-annual Women Lead Here benchmark of executive gender diversity
March 24, 2023 10:54 ET
|
Knight Therapeutics
MONTREAL, March 24, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it has been included on The Globe and Mail’s 2023 Report on...
Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results
March 23, 2023 07:30 ET
|
Knight Therapeutics
MONTREAL, March 23, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported...
Notice of Knight Therapeutics' Fourth Quarter and Year End 2022 Results Conference Call
March 16, 2023 07:30 ET
|
Knight Therapeutics
MONTREAL, March 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and...
Knight Therapeutics Closes US$38.5 million Loan with IFC
December 23, 2022 07:30 ET
|
Knight Therapeutics
MONTREAL, Dec. 23, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has closed a five-year,...
Knight Announces Relaunch of AKYNZEO® in Canada
December 01, 2022 07:30 ET
|
Knight Therapeutics
MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has assumed full...
Knight Therapeutics Reports Third Quarter 2022 Results
November 10, 2022 07:30 ET
|
Knight Therapeutics
MONTREAL, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial...
Knight to Present at Stifel Healthcare Conference
November 09, 2022 18:41 ET
|
Knight Therapeutics
MONTREAL, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, is pleased to announce that Samira...